All In Biotech

BLA 761195 · Argenx Bv

Vyvgart

Efgartigimod Alfa · Injection · Neonatal Fc Receptor Blocker

NovelOrphan

CDER novel approval, Dec 17, 2021: To treat generalized myasthenia gravis

Last checked: Nov 20, 2026Latest source record: May 8, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Dec 17, 2021

Approved uses

4

Original approval plus efficacy supplements

Registered trials

35

9 Phase 3, 9 recruiting

FAERS reports

3,968

3,661 serious, 379 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 13, 2026.

VYVGART is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG). VYVGART is a neonatal Fc receptor blocker indicated for the treatment of adult patients with generalized myasthenia gravis (gMG). ( 1 )

Mechanism: Efgartigimod alfa-fcab is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 8, 2026 Supplement 16 · Efficacy · priority review OrphanLetterLabel
  • Oct 17, 2025 Supplement 12 · Efficacy OrphanLabelLetter
  • Aug 8, 2024 Supplement 4 · Efficacy OrphanLetterLabel
  • Dec 17, 2021 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
1 products under this application
  • VYVGART · EFGARTIGIMOD ALFA 400MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Efgartigimod Alfa" as an intervention, any sponsor and status, largest first.

All 35 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myasthenia gravis785
  • myasthenia gravis crisis455
  • fatigue404
  • dyspnoea301
  • asthenia263
  • fall224
  • drug ineffective216
  • urinary tract infection214
  • muscular weakness199
  • headache192
  • death191
  • dysphagia179

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20205
20213
2022349
20231,194
20241,669
2025451
2026297

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vyvgart (Efgartigimod Alfa-Fcab)

2024 spending

$241M

Beneficiaries

947

4,872 claims

Per beneficiary

$254,275

$307.61 per unit

View as table
YearSpending
2020$0
2021$0
2022$75,471,019
2023$200,002,141
2024$240,798,682

Part B: Vyvgart (Efgartigimod Alfa-Fcab) · HCPCS J9332

2024 spending

$417M

Beneficiaries

1,803

23,690 claims

Per beneficiary

$231,053

2024 ASP limit $32.21 per unit

View as table
YearSpending
2020$0
2021$0
2022$84,680,124
2023$297,337,988
2024$416,589,121

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5 on PubMed

Sponsor: argenx

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.